Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

Beyond mAbs with TandAbs

With enhanced efficacy due to a bispecific mode of action and an excellent safety profile partly due to the absence of an Fc region, TandAbs represent a strong front runner in the race to develop alternatives to first-generation antibody therapeutics.

Uwe Reusch and Stefan Knackmuss at Affimed Therapeutics AG (June 2011)

Keywords: With enhanced efficacy due to a bispecific mode of action and an excellent safety profile partly due to the absence of an Fc region, TandAbs represent a strong front runner in the race to develop alternatives to first-generation antibody therapeutics.

    View full article    |    Back to Biopharma section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |